Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.1117
Abstract: This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D. read more here.
Keywords: medicare part; biosimilar products; utilization filgrastim; infliximab biosimilar ... See more keywords
Close, but no cigar: Biosimilar products and firm regulatory stance
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Healthcare Management"
DOI: 10.1080/20479700.2020.1736790
Abstract: ABSTRACT The medical and pharmaceutical industries must commit to full consensus on biosimilar products. Regulatory recommendations and current resources applied to biosimilars should not be squandered. Additionally, continued lessons learned should be applied for the… read more here.
Keywords: biosimilar; firm regulatory; cigar biosimilar; products firm ... See more keywords
Biosimilar Products in the Modern U.S. Health Care and Regulatory Landscape.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2017.23.12.1255
Abstract: Biosimilars have the potential to greatly reduce medication costs in the United States. As of July 1, 2017, 5 biosimilars have been approved by the FDA, but only 2 are available for purchase. This commentary… read more here.
Keywords: products modern; health care; modern health; health ... See more keywords